From June 3rd to June 6th, CHITOSE Group attended the BIO International Convention 2024 (BIO2024), one of the largest events in the biotechnology sector, held in San Diego, California, USA. This event accommodated companies from a wide range of industries including biopharmaceuticals and related services (CRO, CDMO), featuring 18,500 industry leaders and attracting participants from around the world. CHITOSE delegates were Senior BioEngineer Shinya Kojima, Senior Manager Riztyan, and BioEngineer Kevin Montagne from the Biopharmaceutical, Gene Therapy Unit. 

The partnering and networking events held during the convention provided an opportunity to introduce CHITOSE’s Cell Line Development technology and service, which utilizes uniquely high-performing CHO-MK* cells that can produce large amounts of antibodies and recombinant proteins in a much shorter time compared to conventional CHO cells. The CHITOSE team engaged in face-to-face meetings with bio-pharmaceutical companies to explore potential collaborations and business partnerships.

As CHITOSE is expanding its Biopharmaceutical, Gene Therapy business worldwide, the experiences and connections made at BIO2024 will serve as key steps in that direction.

​​* The establishment of CHO-MK cells was supported by AMED under the Grant Number JP18ae0101054.

Event overview:
Event name: BIO International Convention 2024
Date: June 3rd (Monday) – June 6th (Thursday), 2024
Venue: San Diego Convention Center

Related Articles
Stable Cell Line Development Service for Biopharmaceutical Production
[External] Establishment of a novel cell line, CHO-MK, derived from Chinese hamster ovary tissues for biologics manufacturing